<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163145">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01930396</url>
  </required_header>
  <id_info>
    <org_study_id>13-7822377</org_study_id>
    <nct_id>NCT01930396</nct_id>
  </id_info>
  <brief_title>Use of Tinzaparin for Anticoagulation in Hemodialysis</brief_title>
  <acronym>HEMO-TIN</acronym>
  <official_title>Intermittent HEMOdialysis Anticoagulation With TINzaparin Versus Unfractionated Heparin: A Pilot Multicentre Randomized Controlled Trial (HEMO-TIN Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christine Ribic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Joseph's Healthcare Hamilton</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The HEMO-TIN trial is designed to look at both the safety (bleeding risk) and effectiveness
      (clotting risk) of tinzaparin compared with unfractionated heparin for anticoagulation in
      hemodialysis patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Rate of major, clinically important non-major or minor bleeding</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clotting in extracorporeal dialysis circuit</measure>
    <time_frame>During Hemodialysis (weekly for 26 weeks)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <arm_group>
    <arm_group_label>Tinzaparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Unfractionated Heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tinzaparin</intervention_name>
    <arm_group_label>Tinzaparin</arm_group_label>
    <other_name>Innohep</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Unfractionated Heparin</intervention_name>
    <arm_group_label>Unfractionated Heparin</arm_group_label>
    <other_name>Heparin LEO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Tinzaparin)</intervention_name>
    <description>0.9% Normal Saline</description>
    <arm_group_label>Unfractionated Heparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Unfractionated Heparin)</intervention_name>
    <description>0.9% Normal Saline</description>
    <arm_group_label>Tinzaparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;= 18 years

          -  End stage renal disease maintained on outpatient hemodialysis for &gt;= 3 months

          -  Frequency of hemodialysis: 3 times per week

          -  Anticoagulation with an unfractionated heparin protocol for at least 4 weeks

          -  Patient or legal guardian able to provide written consent

          -  Baseline INR &lt;= 1.3

          -  Baseline platelet count &gt;= 80,000 x 10^9/L

        Exclusion Criteria:

          -  Therapeutic systemic anticoagulation

          -  Clinically apparent bleeding in the last 2 months

          -  High risk of bleeding

          -  Planned major surgery in the next 4 months

          -  Major surgery in the past 48 hours

          -  Pregnant or lactating

          -  Child bearing potential

          -  Allergy/intolerance to heparin or history of heparin induced thrombocytopenia

          -  Current participation in a related randomized drug trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Christine M Ribic, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Joseph's Healthcare Hamilton/McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr. Christine M Ribic, MD, MSc</last_name>
    <phone>905-522-1155</phone>
    <phone_ext>33261</phone_ext>
    <email>christine.ribic@medportal.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Trevor J Wilkieson, MSc</last_name>
    <phone>905-522-1155</phone>
    <phone_ext>35164</phone_ext>
    <email>twilkies@stjoes.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Joseph's Healthcare Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Dr. Christine M Ribic, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr. Mark A Crowther, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr. Azim S Gangji, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr. Deborah J Cook, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr. Michael Walsh, MD, PhD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 27, 2013</lastchanged_date>
  <firstreceived_date>August 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>St. Joseph's Healthcare Hamilton</investigator_affiliation>
    <investigator_full_name>Christine Ribic</investigator_full_name>
    <investigator_title>Nephrologist</investigator_title>
  </responsible_party>
  <keyword>Hemodialysis</keyword>
  <keyword>Anticoagulation</keyword>
  <keyword>Tinzaparin</keyword>
  <keyword>Unfractionated Heparin</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
